Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ASND Relative to the S&P 500

ASND Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Ascendis Pharma A/S (NASD:ASND) seasonal charts above shows that a Buy Date of August 16 and a Sell Date of January 4 has resulted in a geometric average return of 14.66% above the benchmark rate of the S&P 500 Total Return Index over the past 9 years. This seasonal timeframe has shown positive results compared to the benchmark in 9 of those periods. This is an excellent rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 9 years by an average of 5.25% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 9 years of data is available for shares of ASND, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with?unmet medical needs with its Transcon technology. The firm’s product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

To download ASND seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ASND